|
| Press Releases |
|
 |
|
| Tuesday, June 21, 2022 |
|
|
The Mechanism of Action of SinoMab's Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S. |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-listed biopharmaceutical company dedicated to the research, development more info >> |
|
| Wednesday, June 15, 2022 |
|
|
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S. |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Thursday, June 9, 2022 |
|
|
SinoMab Announces IND Application for SN1011 Accepted by NMPA CDE |
| SinoMab BioScience Limited ("SinoMab"; 3681.HK), a Hong Kong-based biopharmaceutical company, an Investigational New Drug application (IND, for neuromyelitis optica spectrum disorder (NMOSD)) for SN1011 has been filed with and accepted by the Center for Drug Evaluation (the CDE) of the National Medical Products Administration of China (NMPA). more info >> |
|
| Wednesday, April 20, 2022 |
|
|
SinoMab Announces IND APPLICATION FOR SN1011 APPROVED BY NMPA |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development more info >> |
|
| Monday, March 14, 2022 |
|
|
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Approved by FDA |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Thursday, February 17, 2022 |
|
|
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Monday, February 7, 2022 |
|
|
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 21 January 2022, more info >> |
|
| Tuesday, January 11, 2022 |
|
|
SinoMab Awarded the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of the "6th Hong Kong Golden Stocks Awards" and the "Listed Company with the Most Growth Potential" in the Selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies" |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Tuesday, November 30, 2021 |
|
|
SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03 |
| SinoMab BioScience Limited ("SinoMab", or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Friday, November 26, 2021 |
|
|
SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health |
| SinoMab BioScience Limited ("SinoMab", or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Prime Minister Paetongtarn Positions Thailand as Regional AI Ethics Leader: Official Launch of AIGPC at the UNESCO Global Forum on the Ethics of AI 2025 
Jun 27, 2025 17:00 HKT/SGT
|
|
|
GA-ASI Announces Investment in Dutch Technology Innovator Arceon
Jun 27, 2025 01:00 HKT/SGT
|
|
|
IBI Announces 23-Fold Surge in Net Profit for FY2025
Jun 26, 2025 22:37 HKT/SGT
|
|
|
Wasion Wins Three Major Smart Power Meter Contracts In Emerging Overseas Markets, Total Contract Value Exceeds HK$940 million
Jun 26, 2025 20:58 HKT/SGT
|
|
|
AEON Credit Reported Rebound Growth in 1QFY2025/26, Net Profit Up 31.3% to HK$109.3 million
Jun 26, 2025 20:01 HKT/SGT
|
|
|
Regina Miracle FY25 Net Profit Up by 28.4% to HK$180 Million
Jun 26, 2025 19:19 HKT/SGT
|
|
|
On Its Centennial: The Occasion of Replacing the Kiswa of the Noble Kaaba Embodies the Kingdom of Saudi Arabia's Enduring Care for the Two Holy Mosques
Jun 26, 2025 15:00 HKT/SGT
|
|
|
World's Premier AI Conference, World AI Show - Indonesia 2025, Arrives in Jakarta to Power Southeast Asia's AI Revolution
Jun 26, 2025 12:31 HKT/SGT
|
|
|
Honda Opens "Honda Software Studio Osaka" as New Software Development Operation
Jun 26, 2025 13:30 JST
|
|
|
Honda Issues "Honda ESG Report 2025"
Jun 26, 2025 13:29 JST
|
|
|
Fujitsu's Uvance Wayfinders consulting empowers customers to evolve business foundations leveraging data and AI
Jun 26, 2025 11:00 JST
|
|
|
XCF Global and Continual Renewable Ventures Announce Memorandum of Understanding to Launch New Rise Australia, a SAF and HVO Platform Powered by XCF
Jun 26, 2025 09:30 HKT/SGT
|
|
|
Investing News Network Strengthens Australian Presence with Appointment of Industry Veteran John Phillips
Jun 26, 2025 00:39 HKT/SGT
|
|
|
Silo Pharma Enters Letter of Intent for JV with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
Jun 25, 2025 21:27 HKT/SGT
|
|
|
Galaxy Payroll Partners with CURRENC to Integrate AI and Stablecoin Technology in HR Solutions
Jun 25, 2025 20:30 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
